GLP-1 Medications for Weight Loss: Which One is Most Efficacy
Tirzepatide, marketed as Zepbound for weight loss, led to greater weight reduction than other GLP-1 medications in a meta-analysis of 15 clinical trials involving 14,000 patients, according to research from the University of Georgia. Participants taking the maximum dose of tirzepatide lost more than 20% of their body weight, compared to 15% for semaglutide (Wegovy) and 8% for liraglutide (Saxenda), the study found.
The review, the first to compare the three FDA-approved GLP-1 drugs for weight loss in non-diabetic patients, highlighted tirzepatide’s dual action on GLP-1 and GIP receptors, which may enhance its effectiveness. Researchers noted that while tirzepatide showed fewer gastrointestinal side effects than other options, the study did not assess long-term weight maintenance after discontinuation.
Why It Matters
GLP-1 medications, originally developed for diabetes, are increasingly used for weight management. A KFF poll found 1 in 8 Americans currently take such drugs, with 1 in 5 having used them previously. The study’s findings could influence prescribing practices, though the FDA had not yet approved an oral version of semaglutide at the time of the review.
What May Happen Next
As demand for weight-loss treatments grows, pharmaceutical companies may prioritize developing formulations with improved efficacy or fewer side effects. However, the study’s authors caution that weight regain is possible after stopping GLP-1 medications, a factor that could shape future research and patient guidelines.
Frequently Asked Questions
What is the primary finding of the study? Tirzepatide caused greater weight loss than semaglutide or liraglutide in non-diabetic patients, with over 20% of participants losing more than 20% of their body weight.
How do the medications differ in administration? Liraglutide requires daily injections, while tirzepatide and semaglutide are administered weekly. An oral version of semaglutide was not evaluated for effectiveness in this study.
What is the current usage of GLP-1 medications in the U.S.? A recent poll found 1 in 8 Americans currently take a GLP-1 medication, with 1 in 5 having used one in the past.
How might the findings impact future weight-loss treatment strategies?